FDA approves J&J prostate cancer treatment

The US Food and Drug Administration (FDA) on Wednesday approved Johnson & Johnson’s Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.

The drug is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, the FDA said in a statement.